CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Mitoguazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002348
NCT00002348Phase 2Completed
CompareCT.gov

Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome

Genzyme, a Sanofi Company·interventional·Posted Aug 31, 2001·Updated Dec 19, 2020

In Brief

A Phase 2 clinical trial evaluating Mitoguazone for Lymphoma, Non-Hodgkin and HIV Infections. Completed, across 1 site.

Detailed Summary

To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing non-Hodgkin's lymphoma (NHL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, HIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Mitoguazonedrug